Table 2

Body composition and bone mineral density at the 3-month visit (time for randomisation)

Treatment A (n = 22)

Treatment B (n = 18)


Body mass index (kg/m2)

27.7 (6.4)

24.7 (3.7)

Fat mass (kg)

30.5 (12.9)

24.4 (7.5)

Fat mass index (kg/m2)

10.9 (4.8)

8.7 (2.9)

Fat (%)

38.8 (8.3)

35.7 (7.9)

Trunk:peripheral fat ratio

1.3 (0.3)

1.2 (0.4)

Trunk fat (kg)

16.4 (7.2)

13.9 (6.6)

Lean body mass (kg)

45.8 (8.8)

43.4 (9.0)

Appendicular lean mass (kg)

19.9 (4.4)

18.7 (4.4)

Fat-free mass (kg)

48.3 (9.1)

45.9 (9.4)

Fat-free mass index (kg/m2)

17.0 (2.5)

16.1 (2.1)

L2 to L4

Bone mineral density (g/cm2)

1.18 (0.19)

1.06 (0.14)

Z score

0.68 (1.40)

-0.66 (0.89)

T score

-0.31 (1.55)

-1.26 (1.18)

Femoral neck

Bone mineral density (g/cm2)

0.98 (0.16)

0.92 (0.11)

Z score

0.50 (1.04)

-0.16 (0.79)

T score

-0.32 (1.25)

-0.82 (0.95)


Data presented as mean (standard deviation). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab.

Engvall et al. Arthritis Research & Therapy 2010 12:R197   doi:10.1186/ar3169

Open Data